
GenScript at Tides Expert Opinion Webinar Series
04-28-2021 / Lumeng Ye, Ph.D. Senior Scientist @Genscript, USA
With the 4th approval on CAR-T therapy (Breyanzi) by FDA in early 2021, ex vivo engineered T cell therapy was proved as a mainstay in cancer treatment.
Register Now